SCHEMBL5044289

SCHEMBL5044289

COCCCn1c(-c2csc(-c3cnccn3)n2)cc(C(=O)O)c1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.42
KLK1 P06870 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CDC7 O00311 1/20 0.37
DBF4 Q9UBU7 1/20 0.37
TRPV4 Q9HBA0 2/20 0.37
HRH3 Q9Y5N1 3/20 0.36
KMT2A Q03164 2/20 0.35
HTT P42858 2/20 0.35
RECQL P46063 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
CRHBP P24387 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5048683 0.94 KLKB1 (0.44) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043461 0.90 KLKB1 (0.42) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5039321 0.84 KLKB1 (0.45) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5044584 0.83 KLKB1 (0.43) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5047149 0.83 ALDH1A1 (0.42) ALDH1A1HPGDKDM4ETRPV4KMT2A
SCHEMBL5043692 0.83 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5043558 0.82 KLKB1 (0.47) KLKB1KLK1HDAC1HDAC8HDAC6
SCHEMBL5046935 0.82 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10KDM4ETRPV4
SCHEMBL5043885 0.81 SREBF2 (0.48) ALDH1A1HPGDCDC7DBF4TRPV4
SCHEMBL5044577 0.81 KLKB1 (0.46) KLKB1KLK1HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R KLKB1 3949/4885KLK1 3547/4885HDAC1 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.